Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
25 juin 2020 08h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC)...
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
19 mars 2020 08h30 HE
|
Celsion CORP
Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 (GLOBE NEWSWIRE) -- Celsion...
Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
04 nov. 2019 08h00 HE
|
Celsion CORP
The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis.The Pooled Progression-Free Survival (PFS) Data is...
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
12 avr. 2019 08h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
New “Multi-Omic” Research Projects Launched to Confront the Complexity of Glioblastoma and Pediatric Brain Tumor Treatment Development
08 nov. 2018 14h25 HE
|
National Brain Tumor Society
Bethesda, MD, Nov. 08, 2018 (GLOBE NEWSWIRE) -- This week, the National Cancer Institute (NCI), the U.S. government's principal agency for cancer research, announced funding for new adult and...
Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors
17 oct. 2018 08h00 HE
|
Cellworks Group, Inc.
Leading Precision Medicine Company Adds to Prestigious Board of Directors, which includes Dr. David Lawrence, Dr. Allen Lichter and Dr. Bill Rutter SAN JOSE, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE)...
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 oct. 2018 17h15 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation...
MMRGlobal Files Additional Cancer Fighting Patent in China Under Expedited Patent Allowance Program
19 août 2013 08h35 HE
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Aug 19, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic...